Short and long-term results after pretransplant high-dose single ATG-fresenius bolus in cadaveric kidney transplantation.
Kaden
J
J
Department of Laboratory Medicine, Friedrichshain Hospital, Berlin, Germany.
Strobelt
V
V
May
G
G
D000818:Animals; D000961:Antilymphocyte Serum / Q000008:administration & dosage / Q000627:therapeutic use*; D001379:Azathioprine / Q000627:therapeutic use; D002102:Cadaver; D016572:Cyclosporine / Q000627:therapeutic use; D005500:Follow-Up Studies; D006085:Graft Survival; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D007275:Injections, Intravenous; D007432:Intraoperative Period; D019169:Jurkat Cells; D016030:Kidney Transplantation / Q000276:immunology*; D008775:Methylprednisolone / Q000627:therapeutic use; D011239:Prednisolone / Q000627:therapeutic use; D011817:Rabbits; D012189:Retrospective Studies; D013997:Time Factors; D014019:Tissue Donors
D000961:Antilymphocyte Serum; D007166:Immunosuppressive Agents; D016572:Cyclosporine; D011239:Prednisolone; D001379:Azathioprine; D008775:Methylprednisolone